153 related articles for article (PubMed ID: 37147986)
21. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
22. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
Foy JP; Bertolus C; Michallet MC; Deneuve S; Incitti R; Bendriss-Vermare N; Albaret MA; Ortiz-Cuaran S; Thomas E; Colombe A; Py C; Gadot N; Michot JP; Fayette J; Viari A; Van den Eynde B; Goudot P; Devouassoux-Shisheboran M; Puisieux A; Caux C; Zrounba P; Lantuejoul S; Saintigny P
Ann Oncol; 2017 Aug; 28(8):1934-1941. PubMed ID: 28460011
[TBL] [Abstract][Full Text] [Related]
23. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.
Schalper KA; Carvajal-Hausdorf D; McLaughlin J; Altan M; Velcheti V; Gaule P; Sanmamed MF; Chen L; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Jan; 23(2):370-378. PubMed ID: 27440266
[TBL] [Abstract][Full Text] [Related]
24. Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth.
Pfeifer S; Schreder M; Bolomsky A; Graffi S; Fuchs D; Sahota SS; Ludwig H; Zojer N
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1821-30. PubMed ID: 22722711
[TBL] [Abstract][Full Text] [Related]
25. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
Dill EA; Dillon PM; Bullock TN; Mills AM
Mod Pathol; 2018 Oct; 31(10):1513-1522. PubMed ID: 29802358
[TBL] [Abstract][Full Text] [Related]
26. Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells.
El Kholy NM; Sallam MM; Ahmed MB; Sallam RM; Asfour IA; Hammouda JA; Habib HZ; Abu-Zahra F
Med Oncol; 2011 Mar; 28(1):270-8. PubMed ID: 20300979
[TBL] [Abstract][Full Text] [Related]
27. GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer.
Wei JL; Wu SY; Yang YS; Xiao Y; Jin X; Xu XE; Hu X; Li DQ; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281987
[TBL] [Abstract][Full Text] [Related]
28. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
29. Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice.
Nakamura N; Hara T; Shimizu M; Mabuchi R; Nagano J; Ohno T; Kochi T; Kubota M; Shirakami Y; Goto N; Ito H; Saito K; Tanaka T; Moriwaki H; Tsurumi H
Int J Hematol; 2015 Sep; 102(3):327-34. PubMed ID: 26243621
[TBL] [Abstract][Full Text] [Related]
30. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
32. Exosomes-carrying Epstein-Barr virus-encoded small RNA-1 induces indoleamine 2, 3-dioxygenase expression in tumor-infiltrating macrophages of oral squamous-cell carcinomas and suppresses T-cell activity by activating RIG-I/IL-6/TNF-α pathway.
Burassakarn A; Srisathaporn S; Pientong C; Wongjampa W; Vatanasapt P; Patarapadungkit N; Ekalaksananan T
Oral Oncol; 2021 Jun; 117():105279. PubMed ID: 33819809
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.
Takamatsu M; Hirata A; Ohtaki H; Hoshi M; Ando T; Ito H; Hatano Y; Tomita H; Kuno T; Saito K; Seishima M; Hara A
Cancer Sci; 2015 Aug; 106(8):1008-15. PubMed ID: 26033215
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
[TBL] [Abstract][Full Text] [Related]
35. Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.
Charehjoo A; Majidpoor J; Mortezaee K
Int Immunopharmacol; 2023 May; 118():110032. PubMed ID: 36933494
[TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-induced antichlamydial indoleamine dioxygenase activity independently.
Currier AR; Ziegler MH; Riley MM; Babcock TA; Telbis VP; Carlin JM
J Interferon Cytokine Res; 2000 Apr; 20(4):369-76. PubMed ID: 10805371
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.
Qian F; Villella J; Wallace PK; Mhawech-Fauceglia P; Tario JD; Andrews C; Matsuzaki J; Valmori D; Ayyoub M; Frederick PJ; Beck A; Liao J; Cheney R; Moysich K; Lele S; Shrikant P; Old LJ; Odunsi K
Cancer Res; 2009 Jul; 69(13):5498-504. PubMed ID: 19491279
[TBL] [Abstract][Full Text] [Related]
38. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
39. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation.
Miyazaki T; Moritake K; Yamada K; Hara N; Osago H; Shibata T; Akiyama Y; Tsuchiya M
J Neurosurg; 2009 Aug; 111(2):230-7. PubMed ID: 19199463
[TBL] [Abstract][Full Text] [Related]
40. The Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated Tumors.
Moreno ACR; Porchia BFMM; Pagni RL; Souza PDC; Pegoraro R; Rodrigues KB; Barros TB; Aps LRMM; de Araújo EF; Calich VLG; Ferreira LCS
Front Immunol; 2018; 9():1914. PubMed ID: 30186285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
